You just read:

Eiger BioPharmaceuticals Announces Completion of Dosing in Phase 2 LOWR HDV - 3 Study at National Institutes of Health (NIH)

News provided by

Eiger BioPharmaceuticals, Inc.

20 Jul, 2016, 08:00 ET